CK Life Sciences Int'l. (Holdings) (HKG:775) Full Year 2024 Results
Key Financial Results
- Revenue: HK$5.52b (up 3.8% from FY 2023).
- Net loss: HK$126.6m (down from HK$17.3m profit in FY 2023).
- HK$0.013 loss per share (down from HK$0.002 profit in FY 2023).
775 Products In Clinical Trials
- Phase II: 1.
- Phase III: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
The primary driver behind last 12 months revenue was the Nutraceuticals segment contributing a total revenue of HK$3.45b (62% of total revenue). Notably, cost of sales worth HK$3.83b amounted to 69% of total revenue thereby underscoring the impact on earnings.Explore how 775's revenue and expenses shape its earnings.
CK Life Sciences Int'l. (Holdings) shares are up 58% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with CK Life Sciences Int'l. (Holdings) (at least 2 which are significant), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.